Krux
March 21, 2026
Earendil Labs Lands $787M for AI Drug Discovery
Published: March 21, 2026 at 12:37 AM
Updated: March 21, 2026 at 12:37 AM
100-word summary
Earendil Labs just closed a $787 million round to speed up its AI-powered antibody discovery platform, with backing from Dimension Capital, DST Global, and notably Sanofi. The pharma giant is doubling down after already committing up to $2.56 billion in a separate licensing deal for two Earendil-discovered drugs. That's the signal: big pharma isn't just licensing AI-designed molecules anymore, they're writing checks to own a piece of the companies making them. The money will fund clinical trials and grow Earendil's team. If AI can compress the decade-long drug discovery timeline, expect more pharma giants to hedge their bets this way.
What happened
Earendil Labs just closed a $787 million round to speed up its AI-powered antibody discovery platform, with backing from Dimension Capital, DST Global, and notably Sanofi. The pharma giant is doubling down after already committing up to $2.56 billion in a separate licensing deal for two Earendil-discovered drugs. That's the signal: big pharma isn't just licensing AI-designed molecules anymore, they're writing checks to own a piece of the companies making them. The money will fund clinical trials and grow Earendil's team.
Why it matters
If AI can compress the decade-long drug discovery timeline, expect more pharma giants to hedge their bets this way.